Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLLISION RELAPSE
2024-515341-41-01Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fluorouracil, capecitabine, oxaliplatin, irinotecan and folinic acid in colorectal cancer liver metastasis (CRLM) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Overall survival. Planned start Dec 2024; status: authorised.
02
Drugs
fluorouracilcapecitabineoxaliplatinirinotecanfolinic acid
03
Conditions
colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on 2024-515341-41-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515341-41-01.